Search - tctmd.com

Displaying 321 - 340 of 361

Sort: Relevancy | Date

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Conference News EuroPCR 2015

Evolving DES Technology May Benefit Diabetic Patients

Caitlin E. Cox

May 19, 2015

News Daily News

‘All-Comers’ Study Shows Survival Benefit of Complete Revascularization in Patients With, Without Diabetes

Caitlin E. Cox

May 08, 2015

News Daily News

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

CREDO-Kyoto: Diabetic Patients With 3-Vessel or Left Main Disease Fare Better With CABG

February 08, 2015

News Daily News

SORT OUT III Substudy Hints at Differences in DES Efficacy Based on Diabetes Status

Todd Neale

November 17, 2014

News Conference News AHA 2014

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

November 16, 2014

News Daily News

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

October 10, 2014

News Daily News

Ischemia Testing Foretells Prognosis in Diabetic Patients with Asymptomatic CAD

Caitlin E. Cox

October 03, 2014

Presentation TCT 2014

Diabetic patients treated with Bioresorbable Vascular Scaffolds show good clinical outcomes at two-year follow-up: A pooled analysis from the ABSORB and SPIRIT trials

Presenter: Javaid Iqbal

September 16, 2014

News Daily News

Hybrid Revascularization a Promising Option for Diabetic Patients

L.A. McKeown

July 24, 2014

News Daily News

El Antidiabético Aleglitazar No Logra Reducir los Resultados Isquémicos de Diabéticos con SCA de Reciente Aparición

L.A. McKeown

April 11, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

News Daily News

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

L.A. McKeown

October 15, 2013

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

Advertisement

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Evolving DES Technology May Benefit Diabetic Patients

‘All-Comers’ Study Shows Survival Benefit of Complete Revascularization in Patients With, Without Diabetes

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

CREDO-Kyoto: Diabetic Patients With 3-Vessel or Left Main Disease Fare Better With CABG

SORT OUT III Substudy Hints at Differences in DES Efficacy Based on Diabetes Status

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

Ischemia Testing Foretells Prognosis in Diabetic Patients with Asymptomatic CAD

Diabetic patients treated with Bioresorbable Vascular Scaffolds show good clinical outcomes at two-year follow-up: A pooled analysis from the ABSORB and SPIRIT trials

Hybrid Revascularization a Promising Option for Diabetic Patients

El Antidiabético Aleglitazar No Logra Reducir los Resultados Isquémicos de Diabéticos con SCA de Reciente Aparición

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content